Apnimed Moves Closer To Phase III With Sleep Apnea Drug
Executive Summary
Apnimed is going to conduct one more Phase II study in sleep apnea, mainly to assess subjective endpoint questionnaires, and then hopes to launch a Phase III program by autumn of 2022.
You may also be interested in...
Finance Watch: VC Mega-Rounds Are Alive And Well
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.
Recall Of Sleep, Ventilator Devices Lead To International Patient Suits For Philips
Patients in Canada and the US are suing Philips over issues related to the company’s recent recall of CPAPs, BiPAPs, and mechanical ventilators.
Finance Watch: Latest Slate Of VC Mega-Deals Led By China-Based Biopharmas
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.